Human Influenza Clinical Trial
Official title:
A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal®) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults.
The present study is designed to evaluate the safety and immunogenicity of trivalent,
surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61
years.
For the immunogenicity endpoint the antibody response to each influenza vaccine antigen will
be evaluated by means of Single Radial Hemolysis (SRH) or Hemagglutination Inhibition (HI)
at approximately 21 days post vaccination.
The vaccine composition will be based on the WHO recommended influenza strains for the 2015
Southern Hemisphere vaccine, and the data from this study are intended to support the use of
this vaccine in future influenza seasons if the recommended vaccine composition remains the
same.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01690637 -
Panama and El Salvador Children's Oseltamivir Study
|
Phase 4 | |
| Completed |
NCT03572491 -
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
|
Phase 3 | |
| Recruiting |
NCT04487041 -
Tfh Dysfunction in HIV and Aging
|
Phase 4 | |
| Completed |
NCT02387294 -
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02600585 -
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
|
N/A | |
| Completed |
NCT01511744 -
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
|
Phase 4 | |
| Completed |
NCT02398097 -
Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects
|
Phase 4 | |
| Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
| Completed |
NCT01677702 -
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
|
N/A | |
| Active, not recruiting |
NCT01096225 -
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
|
N/A | |
| Completed |
NCT00880659 -
Bangladesh Secondary Transmission Handwashing Protocol
|
Phase 2 | |
| Completed |
NCT01879540 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
|
Phase 2 | |
| Completed |
NCT01879553 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
|
Phase 2 | |
| Completed |
NCT01651104 -
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
|
Phase 2 | |
| Completed |
NCT01636102 -
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 2 | |
| Completed |
NCT03448705 -
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
|
Phase 1 | |
| Completed |
NCT02478905 -
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
|
N/A | |
| Recruiting |
NCT04431050 -
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
|
||
| Completed |
NCT01568788 -
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
|
N/A | |
| Completed |
NCT05155319 -
Universal Influenza A Vaccine in Healthy Adults
|
Phase 1 |